Supplementary Material

S1 Supplementary Methods

S1.1 Search strategy and selection criteria

We searched the WHO "COVID-19 Global literature on coronavirus disease" database (MEDLINE, ELSEVIER and the pre-print servers medRxiv and bioRxiv) (100) using search terms that included a range of criteria relating to seroprevalence surveys. The search terms and inclusion and exclusion criteria are described below (Table S1).

S1.2 Search terms

ti:sero\$surv* or ti:serosurv* or ti:seroepidemiolog* or ti:sero\$epidemiolog* or ti:serolog* or ti:seropositiv* or ti:seropositiv* or ti:serosurveillance or ti:sero\$surveillance or ti:seroprevalence or ti:sero\$prevalence or ti:antibody or ti:antibodies or ti:immunity or ti:immunoglobulin OR ab:sero\$surv* or ab:serosurv* or ab:seroepidemiolog* or ab:sero\$epidemiolog* or ab:serolog* or ab:seropositiv* or ab:serosurveillance or ab:serosurveillance or ab:seroprevalence or ab:serosprevalence

Table S1 Inclusion and exclusion criteria

Characteristics	Inclusion criteria	Exclusion criteria
Type of evidence	Published or unpublished scientific literature	Media reports (e.g. news items and press releases), reviews, assessed performance of a test, protocols
	Completed or ongoing serosurveys Report seroprevalence estimates from one or multiple time points	Unrelated to seroprevalence
	Cross-sectional and cohort study designs	Case-control studies, case reports or reviews
Population	Studies of human participants, any age	Studies of non-human participants (i.e animal studies)
	Population groups considered to be representative of the general population	Population groups considered to be unrepresentative of the general population as they had higher risk of infection (e.g healthcare workers and other high-risk groups).
		Studies only of individuals with suspected (e.g. respiratory symptoms) or confirmed SARS-CoV-2 (RT-PCR laboratory confirmation)
Geographical location	WHO European region	Outside of WHO European Region
Languages	Any language	N/A

Table S2: Description of the quality assessment criteria used

Risk of bias criteria	Risk of bias assessment	Risk of bias scoring
Sampling frame: Representative of general population?	Poor (e.g hospital admissions, GP visits, pregnant women, employees)	0
	Weak (eg. blood donors)	1
	Good (e.g household sampling)	2
Sampling frame: Age profile included?	Does not cover those in target population (e.g study of 'all ages' excludes elderly or children)	0
	Study includes all those in target population	1
	Includes all ages (including children)	2
Sampling method: Were study participants sampled appropriate?	Non-random/non-exhaustive (including convenience sampling)	0
	Exhaustive	1
	Random	2
Sample size: Is sample size calculation	Unclear	0
described in methods?	Yes	1
Sample size: Was the sample size adequate?	If at least 300 samples in the study then adequate OR if at least 100 samples per age group (if stratified by age)	1
	If NONE of above OR no mention in methods/unclear	0
Test method: Use of more than one	Yes	1
assays/test?	No	0
Test method 1: Are tests sufficiently accurate? (no clinical validation)	Sensitivity/specificity acceptable* (i.e ELISA: Sn ≥95%, Sp >97% OR POCT: Sn ≥90%, Sp >97%)	1
	Sensitivity/specificity not acceptable (i.e ELISA: Sn <95%, Sp <97% OR POCT: Sn <90%, Sp <97%)	0
Test method 2: Use of commercial tests with clinical validation?	Sensitivity/specificity acceptable* (i.e ELISA: Sn ≥95%, Sp >97% OR POCT: Sn ≥90%, Sp >97%)	2
	Sensitivity/specificity not acceptable (i.e ELISA: Sn <95%, Sp <97% OR POCT: Sn <90%, Sp <97%)	1
Test method 3: Use of in-house assay	Sensitivity/specificity acceptable* (i.e ELISA: Sn ≥95%, Sp >97% OR POCT: Sn ≥90%, Sp >97%)	2
	Sensitivity/specificity not acceptable (i.e ELISA: Sn <95%, Sp <97% OR POCT: Sn <90%, Sp <97%)	1
	No results reported	0
Data analysis: Were the results	Yes and Confidence intervals presented	2
adjusted according to	Yes but no Confidence intervals presented	1
sensitivity/specificity of the serological test?	No/Unclear	0
Overall risk of bias	High risk of bias	1-3
	Moderate risk of bias	4-6
	Low-risk bias	>6

S2 Supplementary Results

Figure S1 Forest plot of the seroprevalence of SARS-CoV-2 antibodies in Community/Household samples with corresponding 95% confidence intervals in WHO European Region (1/1/2020-31/12/2020)

See PDF file attached separately

Figure S2: Forest plot of the seroprevalence of SARS-CoV-2 antibodies in (Top to bottom, Left to Right) a) Residual sera b) Blood donors c) Pregnant or Parturient women d) Patients seeking care (non-COVID) and e) Other populations

See PDF file attached separately

Figure S3 Time point of conducted sero-epidemiology studies in relation to country epidemic activity

See PDF file attached separately